{"entity":{"id":"cho-byoung-chul","kind":"person","name":"Byoung Chul Cho","aka":[],"tldr":"Co-led MARIPOSA, the trial where amivantamab plus lazertinib beat osimertinib, and a leading figure in Asian lung cancer drug development.","summary":"Byoung Chul Cho is Professor in the Division of Medical Oncology and Director of the Yonsei Lung Cancer Center at Severance Hospital, Yonsei University, in Seoul. He co-led MARIPOSA, the trial in which amivantamab plus lazertinib beat osimertinib in previously untreated EGFR-mutated advanced non-small-cell lung cancer, and was a principal investigator for lazertinib from its phase 1 study onwards. He has also led numerous EGFR, MET and immunotherapy trials, and his publications include the MARIPOSA report on amivantamab plus lazertinib. He is a leading figure in Asian lung cancer drug development, with interests in EGFR-mutant disease and bispecific antibodies.","asOf":"2026-09-08","links":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cho%20BC%5BAuthor%5D%20Yonsei%20lung%20cancer"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr","met"],"drugs":["amivantamab","lazertinib"],"companies":[],"institutions":["severance"],"pathways":[],"terms":[],"trials":["mariposa"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor, Division of Medical Oncology; Director, Yonsei Lung Cancer Center","institutionId":"severance","specialisms":["Lung cancer","EGFR-mutant NSCLC","Bispecific antibodies","Drug development"],"profiles":[{"label":"Yonsei Cancer Center","url":"https://sev.severance.healthcare"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cho%20BC%5BAuthor%5D%20Yonsei%20lung%20cancer"}],"papers":[{"title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC (MARIPOSA)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2403614"},{"title":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2404873","doi":"10.1056/NEJMoa2404873"},{"title":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2307980","doi":"10.1056/NEJMoa2307980"},{"title":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1713137","doi":"10.1056/NEJMoa1713137"},{"title":"PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1709937","doi":"10.1056/NEJMoa1709937"}]},"route":"/people/cho-byoung-chul/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ros1-positive-nsclc","kind":"cancer","name":"ROS1-positive non-small-cell lung cancer","route":"/cancers/ros1-positive-nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"drug":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/"}],"institution":[{"id":"severance","kind":"institution","name":"Severance Hospital, Yonsei University","route":"/institutions/severance/"}],"trial":[{"id":"mariposa","kind":"trial","name":"MARIPOSA","route":"/trials/mariposa/"}],"paper":[{"id":"paper-adriatic-nejm-2024","kind":"paper","name":"ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer","route":"/key-papers/paper-adriatic-nejm-2024/"},{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/"},{"id":"paper-flaura-nejm-2018","kind":"paper","name":"FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-flaura-nejm-2018/"},{"id":"paper-mariposa-nejm-2024","kind":"paper","name":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-mariposa-nejm-2024/"},{"id":"paper-pacific-nejm-2017","kind":"paper","name":"PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer","route":"/key-papers/paper-pacific-nejm-2017/"}]}}